Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 5/20 | 0.34 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6673982 | 0.92 | HTT (0.49) | KDM4ELMNAHTTHSD17B10CCR4 | |
| SCHEMBL6677689 | 0.87 | KCNH2 (0.35) | KDM4EHSD17B10RAB9A | |
| SCHEMBL6675559 | 0.86 | GRK6 (0.35) | KDM4EHSD17B10FLT3GRK6 | |
| SCHEMBL6676122 | 0.84 | FLT3 (0.34) | FLT3 | |
| SCHEMBL6673992 | 0.84 | HTR1D (0.35) | — | |
| Hydrochloric Acid SCHEMBL6676590 | 0.81 | BCHE (0.37) | KDM4ETP53 | |
| SCHEMBL6422103 | 0.80 | ALDH1A1 (0.48) | KDM4E | |
| SCHEMBL3385028 | 0.79 | CA12 (0.34) | — | |
| SCHEMBL6676375 | 0.78 | KCNH2 (0.42) | KDM4ELMNAHTTHSD17B10CCR4 | |
| SCHEMBL6679553 | 0.75 | FLT3 (0.41) | KDM4ELMNAHTTHSD17B10CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | KDM4E 1298/4885LMNA 4583/4885HTT 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.